<DOC>
	<DOCNO>NCT01065467</DOCNO>
	<brief_summary>The purpose research study determine safety LBH589 well find side effect may cause effective melanoma . LBH589 drug may slow growth cancer cell kill cancer cell block certain enzyme , protein normally produce cell . These enzyme know play important role development reproduction cancer cell . It believe LBH589 work help promote activity enzymes turn mechanisms cell suppress cell become cancerous .</brief_summary>
	<brief_title>Panobinostat ( LBH589 ) Patients With Metastatic Melanoma</brief_title>
	<detailed_description>- Each treatment cycle last 28 day . During cycle , participant take LBH589 three day week ( Monday , Wednesday Friday ) every week . - During treatment cycle participant physical exam ask general question health specific question problem may . Participants see least weekly first cycle least monthly remain study . - Blood test take check blood cell count , well organs function test infection . These blood sample obtain prior start every cycle least weekly first cycle study . - If participant woman child-bearing potential , ask undergo either blood test provide urine specimen check pregnancy start cycle 1 prior start subsequent cycle . - As possible LBH589 affect rhythm heart , EKGs check frequently participation study . These EKGs perform follow time point : Cycle 1 , day 1 ; Cycle 1 , day 5 ; Cycle 1 , Day 8 ; Cycle 1 day 15 ; day 1 subsequent cycle . - CT scan chest , abdomen pelvis MRI brain perform every 2 cycle every 56 day . - A second sample participant 's tumor remove end first cycle study . - Participants research study least 2 month may continue study benefit drug experience serious side effect .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Histologically cytologically confirm metastatic melanoma Measurable disease 18 year age old ECOG performance status 0 , 1 2 Normal organ marrow function outline protocol Women childbearing potential must negative serum pregnancy test within 7 day first administration study treatment must willing use two method contraception study 3 month last study drug administration Clinically euthyroid Biopsiable disease : Disease must opinion treat investigator biopsiable minimal risk involve Chemotherapy radiotherapy within 4 week prior enter study recover adverse event due agent administer 4 week earlier May receive study agent , anticancer therapy radiation therapy Known brain metastasis history brain metastasis History allergic reaction attribute compound similar chemical biologic composition LBH589 Concomitant use drug risk cause torsades de pointes Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer Patients need valproic acid medical condition study within 5 day prior first LBH589 treatment Impaired cardiac function Uncontrolled hypertension Patients unresolved diarrhea grade 2 great Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral LBH589 Pregnant breastfeed woman Individuals history different malignancy ineligible except follow circumstance : diseasefree least 5 year deem investigator low risk recurrence malignancy ; individual follow cancer eligible diagnose treat within past 5 year : cervical cancer situ , basal cell squamous cell carcinoma skin . Patients know positivity human immunodeficiency virus ( HIV ) hepatitis C Patients significant history noncompliance medical regimen inability grant reliable informed consent Uncontrolled and/or severe intercurrent illness include , limited ongoing active infection psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>LBH589</keyword>
	<keyword>panobinostat</keyword>
</DOC>